Fatal Cardiac Events No Higher With Aromatase Inhibitors for Breast Cancer Therapy

Fatal Cardiac Events No Higher With Aromatase Inhibitors for Breast Cancer Therapy

In the last few years, at least two different meta-analyses have suggested that newer estrogen-lowering aromatase inhibitors used to prevent recurrence of breast cancer may increase the risk of developing cardiovascular disease. But a study published

(Visited 1 times, 1 visits today)
5
Like
Save

Comments

Write a comment

*